Houston Methodist Hospital once again lands on U.S. News & World Report's "Honor Roll." Courtesy of Methodist Hospital/Facebook

Houston's Medical Center is often described as the epicenter of innovation and treatment in the U.S. — as well as the site of Nobel Prize-winning work. Now, a new report offers more bragging rights for the beloved center, as two of its hospitals have landed on a coveted list of the best facilities in the nation.

U.S. News & World Report has released its 2019-2020 list of best hospitals, citing Houston Methodist Hospital and The Menninger Clinic among the top in America.

The publication named Houston Methodist Hospital to its Honor Roll, a list of the top 20 hospitals in the country. Methodist tied for No. 20 with Yale New Haven Hospital in Connecticut, Mayo Clinic-Phoenix, and Hospitals of the University of Pennsylvania-Penn Presbyterian in Philadelphia.

To determine the Honor Roll, U.S. News ranks hospital performance in 16 areas of complex specialty care and rates hospitals in nine bellwether procedures and conditions, such as heart bypass, hip and knee replacement, heart failure, and lung cancer surgery, the publication notes.

This is the third time Methodist has secured the Honor Roll and the eighth year in a row it has been named the No. 1 hospital in Texas. Methodist also ranked No. 1 in the Gulf Coast region and was awarded national rankings in nine adult specialties and recognized as "high performing" for nine adult procedures and conditions.

Meanwhile, in the nationwide survey, The Menninger Clinic ranked No. 5 overall among Best Hospitals for Psychiatry. The institution, which offers treatment services for psychiatric disorders and substance abuse issues, has been ranked by U.S. News for 30 consecutive years, according to a release.

The report distinguishes the best hospitals for patients experiencing difficult-to-treat psychiatric disorders and is based on survey responses from 2017 to 2019 from physicians nationwide who are board certified in psychiatry, according to the publication.

During the three-year survey period, Menninger treated patients from all 50 states and 18 countries through five specialty inpatient programs, says a release. The hospital assists patients ranging from adolescents to adult professionals and hosts a popular annual luncheon featuring a celebrity keynote speaker who has dealt with mental wellness issues.

------

This story originally appeared on CultureMap.com.

Myra Davis is responsible for Texas Children's Hospital's technology and innovation — two completely separate things, she says. Courtesy of TCH

Texas Children's exec to help transform the hospital's approach to innovation

Featured innovator

A few months ago, Myra Davis got a whole other slew of responsibilities with the addition of just one word to her title: Innovation. The senior vice president and chief information and innovation officer of Texas Children's Hospital oversees a team of individuals not only focused on bringing in new technologies and ideas — but maintaining those processes.

Currently, the hospital is in a transition phase looking to better represent its ongoing innovation, as well as bring in new aspects of innovation. Along with Paola Álvarez-Malo, assistant vice president of strategic and business planning at TCH, Davis is looking to keep TCH at the forefront of hospital innovation and pediatric care.

Davis sat down with InnovationMap to discuss the hospital's transformation process and how, while the work together, technoogy and innovation bring two different things to the table.

InnovationMap: What has been your initial focus since assuming the “innovation” part of your title a few months ago?

Myra Davis: When I was appointed, I stepped back and asked myself how we can go about doing this. I knew it was more than the need for technology. We needed to begin to leverage data and a resource that can be agnostic to the organization to help drive strategy.

IM: Why is being both the innovation officer and the information officer important?

MD: Typically, an innovation officer would pass off a new technology to the information officer and hope that they keep it up. Innovation is more than technology. It's about change, and advocating for change in practices, how we hire, how we look at outcomes, and how we look at data. Innovation is radical disruption of how we do things today. It's a full-time job, and then it backs up into including startups and new companies.

IM: Where are you in the transition process?

MD: We're in a discovery phase, which is almost complete. It will drive an outcome of what the structure should look like for an organization of our size and magnitude, and what additional resources we need to have. For example, today to make an appointment, you need to call and make an appointment at the front desk. But we should be disrupting that process and leverage technology. We should have goals of decreasing calls moving forward. We don't yet have the structure to bring those ideas to the table, but that's where I see it going.

IM: How have you seen innovation become a bigger player in health care?

MD: Health care is always a service organization. We're here to serve patients and help them get better. I think clinically, there's always been a need to stay innovative because it's medicine. Now, we're seeing the need to infuse the behaviors of innovative thinking and acting in our operating models to meet the health care model of service. What I mean by that is the cost of care. The models must change because reimbursements are changing, populations are changing, the demand of patients have changed. When I started, we never had patients not wanting to come in for care. Now, patients are saying they don't want to come in because it costs too much. While there's been a plethora of technologies — we have a host of technology systems — but we're realizing we've only scratched the surface with the opportunities we have.

I often talk about the little "i" versus the big "i" in the word "innovation." The little "i" is leveraging what you have already — that's an innovative game changer. Then there's the big "i" and that's the commercialization of a product or partnering with a startup company and they go public. When we say innovation, most people think of that big "i" but it's a spectrum.

IM: What’s the big technology you see disrupting the health care industry?

MD: I think it's data science. It's a major breakthrough. For prescriptive, predictive, and descriptive reasons, we can't afford to keep doing things ourselves. The market is getting competitive, and we must get to decision making faster. You got to go with the data. You can't be so precise it keeps you from being creative, but you have to start with knowledge.

------

Portions of this interview have been edited.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space expands executive team with two C-suite hires

new leaders

Fresh off officially making Texas its legal headquarters, Axiom Space has named two new C-level executives.

The Houston-based spacetech company, which is developing the first commercial space station, announced earlier this month that it had appointed Zach Gitomer as its new chief financial officer and Erick Wegerer as chief information officer.

Gitomer served as vice president of investor relations and capital markets for Axiom from March to June of this year. Before joining Axiom, he held various leadership roles at Bank of America, Merrill Lynch, and Citi, where he supported technology and growth companies, according to Axiom.

"Building era-defining space infrastructure and pioneering the orbital economy is a complex endeavor that requires not just an audacious vision and stellar engineering talent, but the financial infrastructure, discipline, and capital strategy to match," Gitomer shared in a LinkedIn post. "I’m honored to take on this role ... I’m looking forward to partnering with the exceptional leadership team here at Axiom Space during a defining chapter for the company and commercial spaceflight broadly, as well as a crucial period for maintaining U.S. human presence in low-Earth orbit and leadership in space exploration."

Wegerer joins Axiom after most recently serving as CIO of Washington-based Insitu Inc., a subsidiary of Boeing that develops customized unmanned hardware for commercial, government and defense customers.

"My time at Insitu was defined by talented people, meaningful challenges, and work that mattered. I'm grateful for the teams, partners, and leaders who made progress there possible. Stepping into Axiom, I'm energized by the mission, the momentum, and the opportunity to help shape what's next," Wegerer shared.

Photo via LinkedIn

The duo was celebrated on the floor of the New York Stock Exchange last week.

“We are pleased to welcome these exceptional leaders to the Axiom Space team," Axiom CEO Jonathan Cirtain added in the announcement. “Their strong record of helping complex organizations advance their strategic priorities will strengthen our executive team to further advance our core business objectives."

It's been a busy summer for Axiom. The company tacked on an additional $175 million to a previously announced capital raise, bringing the oversubscribed round to a total of more than $525 million, in June.

It also announced plans to open a Japanese subsidiary July 1. It tapped veteran Japanese astronaut Koichi Wakata to lead Axiom Space Japan as chief technology officer in the Asia-Pacific region. It also shared plans to establish Axiom Space Switzerland, a wholly owned subsidiary based in Lucerne that is also expected to begin operations this summer.

Axiom also officially redomiciled its legal headquarters from Delaware to Texas last month. Read more here.

Houston hardtech accelerator names 8 founders to 2026 cohort

hardtech fellows

Hardtech-focused organization Activate has named 50 new members to its 2026 cohort of scientists, which includes eight startups joining Activate Houston.

Activate aims to support scientists at "the outset of their entrepreneurial journey." It partners with U.S.-based funders and research institutions to support its fellows in developing high-impact technology. Its fellows receive a living stipend, research and development funding, connections from Activate's robust network of mentors and access to a curriculum specific to the program for two years.

This year's fellows represent 41 companies from 22 U.S. cities and 11 states.

“This cohort clearly demonstrates that the next industry-defining companies won't choose between modern technology and deep science; they'll be built by combining both,” Cyrus Wadia, CEO of Activate, said in the announcement. “These are the scientists and engineers turning our most urgent global challenges into the companies that will deliver a more sustainable future.”

The Houston fellows are working across the energy, space, AI infrastructure and agriculture sectors. They include:

  • Sophie Clare Broun, founder of Anning Corporation, which is producing clean hydrogen by stimulating naturally occurring geologic deposits
  • Kathy Andersen, founder of Brint Tech, which builds optical sensing systems that quantify hydrogen for infrastructure operators
  • Dorsa Talebi, founder of Kinetiq Drive, which builds rare-earth-free, contact-free electric motors with wireless rotors for small appliances and heavy industry alike
  • Neethu Pottackal, founder of Nivera, which is developing natural, edible coatings made from agricultural byproducts to reduce food waste and extend the shelf life of fresh food
  • Jonathan Huffman, founder of Orbital Arc, which is shrinking spacecraft propulsion to a microchip powerful enough for deep space
  • Tim Lee, founder of Renesin, which develops advanced materials for faster, more efficient AI hardware
  • Joshua Livingston, founder of Selerra Separations, which is developing high-performance membranes that cut the cost and energy consumption of water treatment
  • Wenli Jiang, founder of SwieNitro Recovery, which is developing technology that converts nitrogen-rich waste streams into valuable fertilizer

"Home to the largest concentration of engineers in the United States and a dense ecosystem of Fortune 100 and Fortune 500 companies, Houston is uniquely positioned for scientists tackling large-scale industrial challenges. Activate Houston fellows are connected to the city's deep networks in energy, chemicals, and materials," Activate said in the announcement.

Activate named its inaugural Houston cohort in 2024. It has other hubs in Boston, New York, and Berkley, California—where Activate is headquartered. The organization also offers a virtual and remote cohort, known as Activate Anywhere. Nationally, it has supported 346 fellows and 276 companies since 2015.

Activate Houston is led by managing director Jeremy Pitts, who co-founded Greentown Labs in Boston. It is based out of the Ion. The latest cohort is Activate Houston's third. Read more about the last year's cohort here.

Rice, Houston Methodist award $90K for cancer research projects

seed grants

Rice University’s Synthesis X Center, in partnership with the Houston Methodist Neal Cancer Center, announced earlier this month the organizations would award $90,000 in seed grant funding to two projects that could help fight cancer. One would ease the pain of chemotherapy, while the other could change the way the progression of leukemia is tracked.

“We’re excited to be collaborating with the Neal Cancer Center to support collaborative, novel and interdisciplinary proposals to improve cancer care and outcomes,” Han Xiao, Rice professor of chemistry and the director of the SynthX Center, said in a news release. “Together, we can achieve translational excellence.”

The projects

Chemotherapy is one of the most effective cancer treatments, but it can be hard on the body. The human body doesn’t like being injected with radioactive material, especially the skin around the injection point, which can become extremely irritated. For patients in long-term treatment, the skin irritation can be more than just a bother; it can lead to infections that are dangerous to a compromised immune system.

Angel A Marti, a professor of chemistry at Rice University, and Biana Godin, an associate professor of nanoscience at Houston Methodist Research Institute, are experimenting with metal nanoclusters as a way to block radiation at the injection site. The nanocluster could be applied in a cream or a gel on the skin, serving as a type of shield against the harsh radioactive material.

Meanwhile, Yuan Ma, an assistant professor of chemistry at Rice, and Shu-Hsia Chen, a professor of immunology at Houston Methodist Research Institute, are working with m6A. Discovered in the 1970s, m6A is the most prevalent chemical modifier found in mRNA in mammals. It is prevalent in many cancers, including leukemia.

Ma and Chen are working on measuring the amount of m6A in leukemia to see if it can determine the most effective cancer treatments. The team is also experimenting with ways to shut off m6A to see if it makes current leukemia treatments more effective.

Progress from SynthX

SynthX was first launched in April 2024 to turn research from Rice and Houston Methodist into real-world cancer treatments. Within a year, the center had secured $1.5 million in grant money to work on crossing the blood-brain barrier in brain cancer treatments. These latest awards show that SynthX Center continues to bridge the worlds of research and clinical practice.

“This collaboration reflects a shared commitment to team science in cancer research,” Daniela Matei, the director of the Houston Methodist Neal Cancer Center, added in the release. “These are the types of translational and pioneering projects that lead to transformation in patient care.”'

The SynthX Center awarded $90,000 in seed grants to three teams in 2025 and $80,000 to three teams in 2024.